Tenalisib

Classical Hodgkin Lymphoma

Rhizen Pharmaceuticals SASmall moleculePhase 1Dormant

CC

41/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 81/ 100

Competitive context

63 Active assets in the Classical Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
DACARBAZINE City of Hope Medical Center	Phase 3	BB
VINBLASTINE University of Washington	Phase 2	BB
ETOPOSIDE Masonic Cancer Center, University of Minnesota	Phase 3	BB
Inno-206 Michael Spinner, MD	Phase 3	BB
Tislelizumab Children's Cancer Group, China	Phase 3	BB

View all 50 →

Same molecule, other indications

Tenalisib is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant

B

Indicative ·

60 / 100

T-cell non-Hodgkin lymphomaDormant

B

Indicative ·

59 / 100

B-cell chronic lymphocytic leukemiaDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.